Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. HOOD
10. IBM

Go back to Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
Regeneron (NASDAQ: REGN) Delayed: 612.50 +2.56 (0.42%)
Previous Close $609.94    52 Week High $592.36 
Open $604.46    52 Week Low $325.35 
Day High $613.56    P/E 160.76 
Day Low $594.90    EPS $3.81 
Volume 1,604,280